New hope for leukemia patients after standard treatment fails
NCT ID NCT04926285
Summary
This early-stage study tested the safety and best dose of a two-drug combination (venetoclax and omacetaxine) for adults with acute myeloid leukemia (AML). The trial was for patients whose cancer had returned or stopped responding to a previous treatment that included venetoclax. The main goal was to find the highest dose patients could tolerate without severe side effects, while also checking if the combination could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.